We use some essential cookies to make this website work. We’d like to set additional cookies to understand how you use iwcll.org, remember your settings and improve our services. We also use cookies set by other sites to help us deliver content from their services.
Danielle Brander, A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy (1943)
Home > Resources > Danielle Brander, A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy (1943)
